

ROI in cancer -- How successful has drug discovery and development been in cancer?

Moderator: Mark J. Simon, Advisor, Torrey Partners LLC

Panelists:

George S. Golumbeski, PhD, Senior Vice President, Business Development, Celgene Corporation

Julio Gagne, Director Portfolio & Asset Strategy, Oncology & Immunology, Bristol-Myers Squibb Company


Srinivas Akkaraju, MD, PhD, Managing Director, New Leaf Venture Partners



Oncology is attractive therapeutic area to focus due to increasing development pipeline

Oncology clinical pipeline is the most crowded therapeutic area. Represent 34% of drug candidates


Pipeline drugs by therapeutic area
Number of candidate drugs



¹ Includes anti-neoplastics, supportive-care compounds, and early-stage compounds with "unspecified" indications

Smaller biotech companies with drugs in oncology pipeline represent good partners for consortium model

Oncology pipeline drugs
Number of candidate drugs by pipeline phase



² Roche/Genentech, Amgen, Sanofi-Aventis, Novartis, AZ, Lilly, Pfizer, Merck, Celgene, BMS, Schering-Plough, Bayer, J&J, and GSK

ROI in cancer -- How successful has drug discovery and development been in cancer?

Moderator: Mark J. Simon, Advisor, Torrey Partners LLC

Panelists:

George S. Golumbeski, PhD, Senior Vice President, Business Development, Celgene Corporation

Julio Gagne, Director Portfolio & Asset Strategy, Oncology & Immunology, Bristol-Myers Squibb Company

Srinivas Akkaraju, MD, PhD, Managing Director, New Leaf Venture Partners



DefinedHealth
unconventional insight

